Il 6-7 Giugno si terrà a Roma, presso il Circolo Ufficiali delle Forze Armate d’Italia (Via XX Settembre 2), il 9th LIPIDCLUB & Therapeutic Apheresis 2014 - Interdisciplinary Educational Forum.

Il corso, dal titolo"Updating in Apheresis and Atherosclerosis Research", è valido per l'accreditamento ECM.

L'evento è promosso da Aegerion, Braun, Fresenius Medical Care, Kaneka Pharma Europe, Difass International, Emac ed Haemoclub International a sostegno del LipidClub, dello Studio Multicentrico Italiano LDL-aferesi e del MIGHTY MEDIC - Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances Contrast.

 

 

PROGRAMMA:

 

Venerdì 6 Giugno

09.15 Welcome remarks

Brigadier General Rinaldo Rinaldin - Direttore del Circolo Ufficiali delle Forze Armate d’Italia

Professor Eugenio Gaudio - Preside della Facoltà di Medicina e Farmacia - Università “Sapienza”

Savino Vigliaroli Presidente A.N.I.F. Associazione Nazionale Ipercolesterolemia Familiare

Chairs: U. Julius, C. Stefanutti, P. Moriarty

09.30 The present treatment of elevated Lp(a) and CVD prevention: lipid-apheresis

Patrick Moriarty

09.50 Effect of lipoprotein apheresis on cardiovascular events in patients with elevated Lipoprotein (a) levels

Ulrich Julius

10.10 Familial Hypercholesterolaemia: genetic testing and problems related to the development of a target therapy

Clara Balsano

10.30 Treatment of HoFH by Lomitapide. Long-term extension study: preliminary outcome

Claudia Stefanutti

10.50 Discussion

Coffee break

11.00 Hyperlipidaemia in children

Ornella Guardamagna

11.20 Natural history of FH in Greece: epidemiological findings (clinical/genetic) in 34 Homozygous FH children, teenagers and adults

Euridiki Drogari

11.40 Pitavastatin’s low potential for CYP3A4-mediated drug-to-drug interactions makes it an option for sensitive patients.

Clinical experience from the NK-104-4.02EU Clinical Trial on HeFH Children

Claudia Morozzi, Serafina Di Giacomo

12.10 Treatment of severe Hypertriglyceridaemia and Hyperchylomicronaemia

Wolfang Ries

12.30 To promote health through the European research infrastructures

Elena Bravo

12.50 Discussion

13.15 Closing remarks

 

Sabato 7 Giugno

Chairs: M. Harada Shiba, B. Jaeger, C. Stefanutti

09.00 FH genetic diagnosis by targeted next generation sequencing

Stefano Romeo

09.20 Potential of the H.E.L.P. apheresis in the treatment of ischemic stroke and some other peculiar indications

Beate Jaeger

09.40 Lipoprotein apheresis in UK: current state

Handrean Soran

10.00 Management of pregnancy and delivery in 4 Homozygous FH with LDL apheresis

Mariko Harada Shiba

10.20 Management of pregnancy and delivery for other indications of therapeutic apheresis

Giuseppina Perrone

10.40 Imaging of Cardiovascular Disease. Current status and novel techniques

Gianfranco Gualdi

11.00 Discussion

Coffee break

The MIGHTY MEDIC Working Group General Assembly

Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances Contrast

Chairs: M. Harada Shiba, U. Julius, C. Stefanutti

11.30 1st International survey results - Upcoming scientific activity and research projects

Claudia Stefanutti, Giovanna D’Alessandri

MIGHTY MEDIC MEMBERS

11.50 Morphometric analysis of circulating blood cells in atherosclerosisrelated conditions

Giorgio Bianciardi

12.10 Chronic Kidney Disease as cardiovascular risk predictor. Evidence based clinical management

Fabio Mazza

12.25 Clinical Trials: the role of a Research Nurse

Orietta Macciocca

12.40 Discussion

13.00 CME Questionnaire

13.30 Closing remarks


Seguici sui Social

Iscriviti alla Newsletter

Iscriviti alla Newsletter per ricevere Informazioni, News e Appuntamenti di Osservatorio Malattie Rare.

Sportello Legale OMaR

Tutti i diritti dei talassemici

Le nostre pubblicazioni

Malattie rare e sibling

30 giorni sanità

Speciale Testo Unico Malattie Rare

Guida alle esenzioni per le malattie rare

Con il contributo non condizionante di

Partner Scientifici

Media Partner


Questo sito utilizza cookies per il suo funzionamento. Maggiori informazioni